| Project/Area Number |
22K18203
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 90130:Medical systems-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2024: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2023: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | lymph node metastasis / checkpoint inhibitor / chemoimmunotherapy / リンパ節 / 治療 / 転移 / DDS / 薬物送達 / 肺転移 / 免疫 / 有害事象 |
|---|
| Outline of Research at the Start |
本研究ではLDDSを用いてICIを所属リンパ節に直接投与し,リンパ節およびリンパ節を介した血行性転移に対する超早期治療法の開発, およびirAE発症機序の解明を目的にする. 以下課題に取り組む. (1)LDDSを用いたICIの所属リンパ節投与による治療適用範囲をリンパ節転移から遠隔転移の制御・予防まで拡大する. (2) LDDSの治療効果を高めるためにICIと抗がん剤との重畳効果を検討する. (3) 治療効果を判定するために新たな薬力学的評価因子であるanenestic バイオマーカーを同定する.
|
| Outline of Annual Research Achievements |
Immunotherapy using immune checkpoint inhibitors (ICIs) is revolutionizing cancer metastasis treatment. However, few head and neck cancer (HNC) patients respond to ICIs with a high incidence of immune-related Adverse Events (irAEs). Still, a majority of them fail to respond. We created experimental mouse model by injecting luciferase expressing tumor cells and ICIs were injected as mono- or sequentially with combination of docetaxel. Treatment effects were evaluated over time, and final confirmation was made histologically along with irAEs. We found more significant tumor inhibition in the chemo-immunotherapy groups than in mono-immunotherapy.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
At this moment, we have completed ICI effects on metastatic LN mouse model as a monotherapy or chemoimmunotherapy. We observed inhibition of tumor progression in the lymphatic drug delivery system delivered mono-ICI with he reduced irAEs. The chemoimmunotherapy group investigation is still on going as planned
|
| Strategy for Future Research Activity |
We plan to finish effect of chemoimmunotherapy for metastatic LN mouse model. Therefore, planning to broaden the effect of ICIs or chemoimmunotherapy for LN resected mouse model.
|
